Health ❯ Pharmaceuticals

Drug Development

Clinical Trials Weight Loss Drugs Regulatory Affairs Clinical Research Obesity Treatments Oncology FDA Approval Cancer Drugs Market Competition Generic Drugs

GLP-1 Boom Puts Pharma at Risk and Shifts Obesity Care, New Data Show

New analyses link a surge in weight-loss drug use to concentrated pipeline returns that coincide with fewer bariatric surgeries.

FDA Chief Makary Defends Drug Calls as Report Flags Strained White House Ties

Stories older than 24h

HHS Push to Ease Peptide Curbs Spurs FDA Review and Investor Bets

Google Cloud Unveils Gemini Enterprise Agent Platform With Security Controls, Partner Fund and New TPUs

Corcept Investors Face Today’s Lead‑Plaintiff Deadline in Securities Case Over Relacorilant Disclosures

Medicus Pharma Reports Long-Acting Hormone Control in Phase 1 Teverelix Data

Corcept Investors Face April 21 Deadline to Seek Lead Role in Securities Suit Over Relacorilant

Allogene Soars on Early ALPHA3 Readout Showing Strong MRD Edge and Clean Safety

UniQure Investors Face Lead‑Plaintiff Deadline in Securities Fraud Case

FDA Rejects Replimune’s Melanoma Virus Therapy Again for Insufficient Evidence

India’s Generic Semaglutide Wave Eats Into Mounjaro’s Lead as Novo Holds Share

Trump Imposes Up to 100% Tariffs on Patented Drugs With Paths to Lower Rates

Law Firms Urge Corcept Investors To Seek Lead Plaintiff Role In Securities Suit Over Relacorilant

Lilly Strikes $2.75 Billion Deal for Insilico’s AI-Designed Oral Drugs

Ultragenyx Hit With Securities Class Action Over Failed Phase III Trials

AstraZeneca’s COPD Antibody Tozorakimab Succeeds in Two Phase 3 Trials

Cancer Study Maps Brain Metastasis Switch and Identifies Ibudilast as a Repurposing Candidate

Law Firms Urge Corcept Investors To Seek Lead Role In Securities Case Before April 21

Gilead to Buy Ouro Medicines for $1.675 Billion Upfront to Advance Autoimmune T‑Cell Engager

Law Firms Seek Soleno Investors Ahead of May 5 Lead‑Plaintiff Deadline